HALO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Halozyme Therapeutics Inc (HALO) is not a strong buy for a beginner, long-term investor at this moment. Despite positive analyst ratings and strong revenue growth, the company's declining net income, EPS, and gross margin, coupled with hedge fund selling and weak technical indicators, suggest caution. The lack of strong trading signals and mixed catalysts further reinforce a hold stance.
The MACD is negative and expanding (-0.818), RSI is neutral at 22.166, and moving averages are converging. The stock is trading near its S1 support level of 67.263, with resistance at 69.652. Overall, the technical indicators do not suggest a strong upward trend.
FDA approval of Tecvayli in combination with Darzalex Faspro, which could drive royalty revenues.
Positive analyst ratings with increased price targets (up to $
and strong forward guidance.
Revenue growth of 51.60% YoY in Q4 2025.
Hedge funds are aggressively selling, with a 4215.85% increase in selling activity.
Financial performance shows a significant drop in net income (-203.34% YoY) and EPS (-213.21% YoY).
Gross margin declined by 3.18% YoY.
Weak technical indicators with a negative MACD and neutral RSI.
In Q4 2025, revenue increased by 51.60% YoY to $451.77M. However, net income dropped to -$141.59M (-203.34% YoY), EPS fell to -1.2 (-213.21% YoY), and gross margin declined to 77.39% (-3.18% YoY).
Analysts are bullish on HALO, with multiple firms raising price targets (up to $94) and maintaining Buy or Overweight ratings. Positive sentiment is driven by strong Q4 results, expanding partnerships, and promising future guidance.
